PR001403 (Project)

Description:Analysis of metabolite relative abundance in blood plasma from 316 individuals with trisomy 21 (T21, Down syndrome) and 103 euploid controls. This dataset focuses on hydrophilic metabolites and oxylipins and is part of the Human Trisome Project (HTP, http://www.trisome.org/) run by the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz Medical Campus. This data is generated from samples matched at the blood draw to multiple omics datasets including proteomics, cytokine profiling, RNA-seq, and mass cytometry. The HTP is an in-depth study of people with Down syndrome using the latest technologies in precision medicine. The goal of the HTP is to enable advanced therapeutic approaches to enhance the quality of life and extend the lifespan of those with trisomy 21 through the study of the co-occurring conditions of Down syndrome. The HTP leverages a multidisciplinary team of biomedical researchers, clinicians and data scientists located across multiple departments, divisions, institutes and centers at the University of Colorado who work together toward a single goal: to decipher why people with trisomy 21 have a different disease spectrum, being predisposed to some medical conditions while being protected from others. The HTP Biobank provides de-identified samples and clinical information to collaborators that are necessary for investigations that advance our understanding of several co-occurring medical conditions in Down syndrome. Studies using samples and data from the HTP Biobank are enabling the development of novel diagnostics and therapeutic approaches, serving not only individuals with Down syndrome, but also the billions worldwide affected by conditions that commonly co-occur in Down syndrome. This collaborative and multi-disciplinary model allows for one of the largest and most comprehensive studies of individuals with Down syndrome to date, including extensive characterization at the clinical, physiological, cellular and molecular levels.